@diggahtv's GHK-Cu peptide claims need some context

What did @diggahtv actually say?

Honestly? It's hard to tell. The transcript from this video is nearly incomprehensible. Phrases like "the taste of Dutch is really normal" and references to gaming and microphones suggest either a severe auto-captioning failure, a language barrier, or content that has nothing to do with GHK-Cu peptides at all. There are no identifiable medical claims in the transcript.

The hashtags (#peptid, #ghkcu) place this video squarely in the peptide optimization space on TikTok, but the actual spoken content does not appear to discuss peptide mechanisms, dosing, benefits, or research. Without a coherent set of claims to evaluate, this fact-check has to pivot to covering what GHK-Cu actually is, so viewers who landed here from that video get something useful.

Does the science back this up?

There is no specific claim from this video to evaluate against the literature. But GHK-Cu does have a real research base worth knowing about, even if this video did not articulate it.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring peptide found in human plasma, saliva, and urine. Plasma concentrations decline significantly with age, dropping from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60 (Pickart et al., 2015, Organogenesis). In laboratory and animal models, GHK-Cu has shown activity related to wound healing, collagen synthesis stimulation, and anti-inflammatory signaling. Pickart and Margolina (2018, Frontiers in Aging Neuroscience) reviewed its gene expression effects across over 4,000 human genes. That is interesting data. It is not the same as proven clinical outcomes in humans.

What did they get wrong (or right)?

Because no coherent claims were made, there is nothing specific to correct. That is itself a problem. Videos tagged with peptide-related hashtags reaching 52,000 views carry an implicit responsibility to communicate something accurate. Viewers searching for GHK-Cu information deserve better than indecipherable content.

What the broader GHK-Cu content ecosystem gets wrong regularly is worth noting here. Common errors include presenting animal or in-vitro data as settled human evidence, implying compounded topical or injectable GHK-Cu is equivalent in bioavailability to endogenous peptide activity, and treating gene expression data as synonymous with clinical outcomes. None of those shortcuts are supported by current evidence. Most human trials on GHK-Cu remain small, short, and focused on topical skin applications rather than systemic anti-aging effects.

What should you actually know?

GHK-Cu is one of the more researched peptides in the longevity and dermatology space, but its hype has outpaced its human clinical data by a wide margin.

Here is where the evidence actually stands. Topical GHK-Cu has the strongest human data, particularly for skin quality and wound healing. Leyden et al. and subsequent industry-funded trials have shown improvements in fine lines and skin density, though industry funding is a real bias risk. Systemic or injectable use is largely extrapolated from animal studies and gene expression analysis. The FDA has not approved GHK-Cu for any indication. Compounded versions sold through telehealth are not FDA-approved drugs, and quality varies by compounding pharmacy. Anyone considering GHK-Cu peptide therapy should have that conversation with a licensed provider who can review their full health picture, not base decisions on a TikTok video, especially one that cannot be understood.